Incyte brings Phase 3 tafasitamab data to ASCO 2026, but will frontMIND reshape first-line DLBCL treatment?
Incyte’s Phase 3 tafasitamab data are headed to ASCO 2026. Read what frontMIND could change for first-line DLBCL and what risks still remain.
Incyte’s Phase 3 tafasitamab data are headed to ASCO 2026. Read what frontMIND could change for first-line DLBCL and what risks still remain.